Staar Surgical (STAA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Defender Capital LLC. purchased a new stake in shares of STAAR Surgical Company (NASDAQ: STAA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 668,222 shares of the medical instruments supplier's stock, valued at approximately $15,429,000. STAAR Surgical accounts for
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 316,017 shares of the business's stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director owned
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 299,432 shares of the business's stock in a transaction on Thursday, March 12th. The shares were purchased at an average price of $18.12 per share, with a total value of $5,425,707.84. Following the completion of the purchase, the director owned 15,807,825 shares
STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript
Staar Surgical (STAA) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to a loss of $0.5 per share a year ago.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR's results release can be found here: https://investors.staar.com/news-and-events/press-releases. Fellow Shareholders, This past month marked an important transition for our company as we stepped into the roles of Interi.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/news-and-events/press-releases. Fourth Quarter 2025 Financial Overview.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This achievement underscores the growing global preference for lens-based solutions in refractive vision correction as.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR S.
